期刊文献+

慢性阻塞性肺疾病合并不成比例肺动脉高压患者血浆D-二聚体水平测定及分析 被引量:3

Detection and significance of plasma D-dimer in chronic obstructive pulmonary disease with out of proportion in pulmonary hypertension
原文传递
导出
摘要 目的探讨慢性阻塞性肺疾病(COPD)合并不成比例肺动脉高压患者血液是否呈高凝状态。方法选择稳定期COPD合并肺动脉高压(PH)患者46例,其中COPD合并不成比例PH患者9例(A组),其余COPD合并PH患者37例(B组),具有可比条件的正常中老年人20例为正常对照组(C组),分别检测三组受检查血浆D-二聚体水平。结果 A组血浆D-二聚体水平显著高于B组(P<0.05),也显著高于C组(正常对照组)(P<0.05);B组血浆D-二聚体水平与C组无明显差异(P>0.05)。COPD合并不成比例PH组患者平均肺动脉压与血浆D-二聚体水平有显著相关性(r=0.86,P<0.01)。结论 COPD合并不成比例PH患者血液呈高凝状态,理论上可行抗凝治疗。 Objective To observe the content of D-dimer in chronic obstructive pulmonary disease (COPD) with out of proportion in pulmonary hypertension ( PH ). To investigate the changes of coagulation function in these patients. Methods The content of D-dimer was examinated in 37 COPD with PH patients( B group), 9 COPD with out of proportion PH patients (A group) and 20 normal health people ( C group). Results The content of D-dimer in A group was distenetly higher than that in B group and control group ( P 〈 0.05 ). The content of D-dimer was not significantly different between B group and control group( P 〉 0.05 ). There was significant correlation between mean pulmonary arterial pressure and plasma D-dimer in COPD with out of proportion PH patients ( r = 0.86, P 〈 0.01 ). Conclusion The blood of COPD with out of proportion in PH is in a hypercoagulatory state ,these patients potentially should be treated with anticoagulant drugs.
出处 《中华肺部疾病杂志(电子版)》 CAS 2013年第3期39-42,共4页 Chinese Journal of Lung Diseases(Electronic Edition)
关键词 肺疾病 慢性阻塞性 肺动脉高压 D-二聚体 Chronic obstructive pulmonary disease Pulmonary hypertension D-dimer
  • 相关文献

参考文献20

  • 1Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD[J] . Eur Hespir J, 2008, 32(5) : 1371-1385.
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8230
  • 3Silva DR, Coelho AC, Gazzana MB, et al. D-dimer levels in stable COPD patients: a case-control study [J] . COPD, 2012, 9( 4) : 426- 431.
  • 4Zakynthinos E, Daniil Z, Papanikolaou J, et al. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets [J] . CUIT Drug Targets, 2011,12(4): 501-513.
  • 5Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy [J] . N Eng! J Med, 2006, 355(17): 1780-1789.
  • 6Gunen H, Gulbas G, In E, et al. Venous thromboemboli and exacerbations of COPD[ J]. Eur RespirJ, 2010, 35( 6) : 1243-1248.
  • 7Sullivan JH, Hubbard R, Liu SL, et al. A community study of the effect of particulate matter on blood measures of inflammation and thrombosis in an elderly population [J] . Environ Health, 2007, 6 (2): 3-8.
  • 8Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension [ J ] . Chest, 2009, 135 (2) : 536-537.
  • 9Chhahm SK. Pulrmnary hypertension associated with chronic obstructive pulmonary disease [ J]. Indian J Chest Dis Allied Sci, 2010, 52 (1): 2940.
  • 10Barbera JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management[J]. Drugs, 2009, 69(9): 1153-1171.

二级参考文献7

共引文献8229

同被引文献29

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部